Effect of temozolomide in patients with metastatic bronchial carcinoids.
Neuroendocrinology
; 98(2): 151-5, 2013.
Article
in En
| MEDLINE
| ID: mdl-23969949
ABSTRACT
INTRODUCTION:
Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment so far have been disappointing. A previous study from our center indicated that temozolomide might be of value. MATERIALS ANDMETHODS:
All patients with progressive metastatic bronchial carcinoid treated with temozolomide as monotherapy at our center between 2004 and 2010 (n = 31) were included in this retrospective study. 14 tumors were classified as typical and 15 as atypical carcinoids, whereas 2 tumors could not be classified. Temozolomide was given on 5 consecutive days every 4 weeks. Toxicity was evaluable in 28 of 31 patients, and 22 patients were evaluable by RECIST 1.1.RESULTS:
There were no complete responses. A partial response was seen in 3 patients (14%), stable disease in 11 (52%) and progressive disease in 7 patients (33%). Median progression-free survival was 5.3 months and median overall survival was 23.2 months from the start of temozolomide. Toxicities grade 3-4 were noted in 4 patients, thrombocytopenia (n = 3) and leukopenia (n = 1).CONCLUSION:
Temozolomide as monotherapy shows activity in metastatic bronchial carcinoids. Regimens combining temozolomide with other agents (e.g. capecitabine and/or bevacizumab, everolimus, radiolabeled somatostatin analogues) should be further studied in these patients.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bronchial Neoplasms
/
Carcinoid Tumor
/
Antineoplastic Agents, Alkylating
/
Dacarbazine
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Neuroendocrinology
Year:
2013
Type:
Article
Affiliation country:
Sweden